IDEAYA Receives IND Clearance Enabling Phase 1/2 Clinical Trial For Combination Of IDE397 And AMG 193 In MTAP-Deletion Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
IDEAYA Biosciences has received IND clearance for a Phase 1/2 clinical trial of the combination of IDE397 and AMG 193 in MTAP-deletion solid tumors. The trial, sponsored by Amgen, aims to evaluate the potential first-in-class synthetic lethality combination targeting MAT2A and PRMT5.
May 22, 2023 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen is sponsoring the Phase 1/2 clinical trial of IDE397 and AMG 193 in MTAP-deletion solid tumors, conducted by IDEAYA Biosciences.
As the sponsor of the clinical trial, Amgen is investing in the development of a potential first-in-class treatment for MTAP-deletion solid tumors. The IND clearance is a positive development for the trial, which could have a positive short-term impact on Amgen's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
IDEAYA Biosciences receives IND clearance for a Phase 1/2 clinical trial of IDE397 and AMG 193 in MTAP-deletion solid tumors, sponsored by Amgen.
The IND clearance allows IDEAYA Biosciences to proceed with the clinical trial, which could potentially lead to a first-in-class treatment for MTAP-deletion solid tumors. This positive development is likely to have a positive short-term impact on IDYA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100